How I treat my inflammatory bowel disease-patients with thiopurines?

Berrie Meijer, Chris JJ Mulder, Adriaan A van Bodegraven, Nanne KH de Boer

Berrie Meijer, Chris JJ Mulder, Nanne KH de Boer, Department of Gastroenterology and Hepatology, VU University Medical Center, 1007 MB, Amsterdam, The Netherlands

Adriaan A van Bodegraven, Department of Gastroenterology, Geriatrics, Internal and Intensive Care Medicine (Co-MIK), Zuyderland Medical Center, 6130 MB, Sittard-Geleen, The Netherlands

Author contributions: de Boer NKH was the guarantor of the article; Meijer B completed the first draft of the manuscript; Mulder CJJ, van Bodegraven AA and de Boer NKH critically revised the manuscript; Meijer B finalized the article.

Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Correspondence to: Nanne KH de Boer, MD, PhD, Department of Gastroenterology and Hepatology, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands. khn.deboer@vumc.nl
Telephone: +31-20-4440613
Fax: +31-20-4440554
Received: July 21, 2016
Peer-review started: July 21, 2016
First decision: September 5, 2016
Revised: September 12, 2016
Accepted: October 5, 2016
Article in press: October 7, 2016
Published online: November 6, 2016

Abstract

Thiopurines are essential drugs to maintain remission in patients with inflammatory bowel disease (IBD). Thiopurines used in IBD are azathioprine (2.0-2.5 mg/kg), mercaptopurine (1.0-1.5 mg/kg) and thioguanine (0.2-0.3 mg/kg). However, mainly due to numerous adverse events associated with thiopurine use, almost 50% of the patients have to discontinue conventional thiopurine treatment. Extensive monitoring and the application of several treatment strategies, such as split-dose administration, co-administration with allopurinol or dose reduction/increase, may increase the chance of successful therapy. With this review, we provide practical information on how thiopurines are initiated and maintained in two thiopurine research centers in The Netherlands. We provide clinical information concerning safety issues, indications and management of therapy that may serve as a guide for the administration of thiopurines in IBD patients in daily practice.

Key words: Thiopurines; Azathioprine; Mercaptopurine; Thioguanine; Inflammatory bowel disease; Therapeutic drug monitoring; Pregnancy; Metabolites

© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Conventional thiopurine therapy with azathioprine and mercaptopurine in inflammatory bowel disease is associated with several adverse events causing cessation of therapy in up to half of the patients. On the contrary, thiopurine therapy is often unnecessarily discontinued. In this practical review, we provide information on how thiopurine therapy is initiated and maintained using periodical laboratory tests and the application of various treatment strategies (including the administration of a third thiopurine; thioguanine), based on the experience in the two expert thiopurine centers in The Netherlands.
also account for inhibition of anti-apoptotic effects and the DNA (thus achieving an anti-metabolic effect), but synthetase (GMPS). The 6-TGN can be incorporated in hydrogenase (IMPD) and guanosine monophosphate transferase (HGPRT), inosine monophosphate dehydrogenase (XOR), and thiopurine-S-methyltransferase (TPMT), converting MP into 6-thiouric acid (6-TUA) and 6-methylmercaptopurine (6-MMP), respectively. The remaining concentration of MP is withdrawn into MP by the enzyme glutathione S-transferase, after 6-thioguanine nucleotides (6-TGN)

INTRODUCTION

Inflammatory bowel disease (IBD) is a chronic condition of the gastrointestinal tract which is characterized by episodes of remission and relapses and encompasses both Crohn's disease (CD) and ulcerative colitis (UC). In the management of IBD, thiouirines [i.e., azathioprine (AZA), mercaptopurine (MP) and thioguanine (TG)] play an important role in clinical practice, mainly in order to maintain remission\(^1\)-\(^4\). Over the past decades, extensive research has been performed to elucidate the complex metabolism of thiouirine derivatives\(^5\)-\(^7\). In this article, we demonstrate and discuss the way we use thiouirine therapy in the treatment of adult IBD patients in two referral centers in The Netherlands in daily practice. For information about thiouirine therapy in pediatric IBD, we refer to reviews focused on this patient group\(^8\)-\(^10\).

DISCOVERY OF THIOPURINES

Thiouirines were firstly described in the early 1950s by Gertrude Elion and George Hitchings, primarily as antimetabolite therapy\(^1\). Initially, thiouirines were used in the treatment of acute lymphatic leukemia in children and in the prevention of organ transplant rejection. The first IBD patient treated with thiouirines has been described by Dr. Bean\(^1\) in 1962. At this moment, thiouirines are used in a variety of autoimmune disorders and hematologic malignancies\(^1\),\(^3\),\(^1\)\(^1\).

PHARMACOLOGY OF THIOPURINES

The thiouirine derivatives AZA, MP and TG are all prodrugs which are subsequently converted into the allegedly most important pharmacologically active end-metabolites, 6-thioguanine nucleotides (6-TGN)\(^9\). AZA is converted into MP by the enzyme glutathione S-transferase, after which MP is metabolized by three competing enzymatic systems. First, a part of the concentration MP is withdrawn from bioavailability by xanthine oxidase (XO) and thiouirine-S-methyltransferase (TPMT), converting MP into 6-thiouric acid (6-TUA) and 6-methylmercaptopurine (6-MMP), respectively. The remaining concentration of MP is metabolized via the purine salvage pathway into 6-TGN by a cascade of hypoxanthine-guanine phosphoribosyl transferase (HGPRT), inosine monophosphate dehydrogenase (IMP\(_d\)) and guanosine monophosphate synthetase (GMPS). The 6-TGN can be incorporated in the DNA (thus achieving an anti-metabolic effect), but also account for inhibition of anti-apoptotic effects and down-regulation of pro-inflammatory cytokines. In daily practice, we measure 6-TGN and 6-MMP in red blood cells (RBC), which is mainly due to the fact that in patients with leukemia, the original indication for thiouirine therapy, successful treatment with thiouirines leads to the unavailability of leukocytes\(^1\),\(^1\)\(^5\),\(^1\)\(^7\),\(^1\)\(^8\),\(^1\)\(^9\).

In contrast to AZA and MP, the metabolism of TG is less extensive as TG is directly converted into 6-TGN by HGPRT. Whether TG is also withdrawn from bioavailability by the effect of TPMT and XO, this effect is relatively smaller than in AZA and MP, leaving a larger portion of TG available for (direct) conversion into 6-TGN (Figure 1)\(^1\),\(^5\),\(^1\)\(^6\),\(^1\)\(^7\).

INDICATIONS OF THIOPURINE THERAPY

When treating IBD patients in our centers, we apply the therapeutic approach known as accelerated step up care in both CD and UC\(^1\). Conventional thiouirines (i.e., AZA and MP) do not play a standard role in the active phase of CD and UC as such, however it may be added to induction course therapy with corticosteroids in those patients who are suspected of having a more severe or prolonged disease course. In patients with only mildly active disease with good reaction on initial induction therapy, thiouirines do not have to be initiated straight away\(^1\)\(^9\). However, in those patients with a relapse of disease despite two induction courses of corticosteroids, thiouirines are required to maintain remission\(^1\)\(^0\). Furthermore, thiouirines are co-administered as a routine to treatment with anti-TNF therapy in our centers, in line with recent observations from the SONIC trial\(^2\)-\(^4\),\(^2\)\(^1\). In those patients receiving vedolizumab (Entyvio\(^6\)) evidence is scarce whether to (dis)continue simultaneous thiouirine therapy\(^2\)\(^2\),\(^2\)\(^3\). In our centers, we continue thiouirine therapy in the majority of patients, since patients receiving vedolizumab are likely to have highly complex disease in which vedolizumab is often initiated as rescue drug. Additionally, in line with the observations in the SONIC trial in patients receiving infliximab and adalimumab, we presume that thiouirines might have a protecting effect on the development of antibodies against vedolizumab\(^2\)\(^4\),\(^2\)\(^9\). Finally, thiouirines are administered in surgical CD patients to prevent post-surgical recurrence, especially in complex patients with fistulizing disease or multiple surgical interventions\(^3\).

Thiouirine therapy is initiated in a dosage of 2.0-2.5 mg/kg for AZA or 1.0-1.5 mg/kg for MP, starting with 50 mg/d in the first week and increasing to full-dose when patients experience no adverse effects on low-dose therapy\(^1\)\(^1\). In those patients in whom thiouirines were co-administered next to induction corticosteroid therapy, the steroids are tapered down in 2-3 mo.

In our center, we prefer to initiate thiouirine therapy using MP, based on results of several rechallenge studies\(^2\)\(^6\)-\(^2\)\(^1\). Furthermore, in those patients with mild adverse events (i.e., no severe myelotoxicity or pancreatitis) on MP therapy, we rechallenge these patients with MP with low threshold.
TOXICITY OF THIOPURINE THERAPY

As thiopurines are associated with a broad spectrum of adverse events (i.e., flu-like symptoms, arthralgia, gastrointestinal complaints, rash, pancreatitis, hepatotoxicity and myelotoxicity), one of the applied strategies to reduce the risk of developing adverse events is to measure TPMT activity before initiating thiopurine therapy, to identify patients at risk of developing adverse events based on an aberrant thiopurine metabolism [7, 16, 32, 33]. Literature reports show that 1:300 (Caucasian) individuals have TPMT deficiency, making them at risk for developing (severe) myelosuppression due to preferential 6-TGN formation [34].

In our centers, however, TPMT activity is not determined as we initiate thiopurine therapy with a low-dose start up scheme. Furthermore, many patients with normal TPMT activity could still develop adverse events of thiopurine therapy [32, 35, 36]. For this reason amongst others, we choose to extensively monitor laboratory and clinical parameters in the first three months after initiation of thiopurine therapy. At week 0, 1, 2, 4, 8 and 12, hematologic and hepatic parameters are being measured, as well as creatinine and C-reactive protein (Table 1). After initiation, these parameters are determined each 3-4 mo during thiopurine maintenance therapy.

MEASURING METABOLITES

Measurement of thiopurine metabolites (6-TGN and 6-MMP) is not performed routinely in clinical practice at our centers. In those patients who experience adverse...
events or non-response to treatment, metabolite levels may explain why these patients are intolerant or resistant to therapy (Table 2). Based on these results, individual treatment strategies (i.e., split-dose administration, dose reduction/increase, the addition of mesalazine or allopurinol to a 25%-33% dose of the original thiopurine in patients with an altered thiopurine metabolism, so-called “skewers”) may be applied

| 6-TGN (pmol/8 × 10^8 RBC) | 6-MMP (pmol/8 × 10^8 RBC) | Non-response | Adverse event (dose-dependent) | Recommendation |
|---------------------------|---------------------------|--------------|-------------------------------|---------------|
| <= 230                    | <= 5700                   | Non-compliance | Not expected                   | Gain compliance |
| < 230                     | < 5700                    | Non-compliance/under dosing | Not expected                   | Gain compliance/increase dose |
| 230-400                   | < 5700                    | Possible resistance to thiopurine therapy | Not expected                   | Increase dose1 or change therapy |
| > 400                     | < 5700                    | Therapy resistance   | Myelotoxicity                  | Change therapy |
| < 230                     | > 5700                    | Shunting             | Hepatotoxicity                 | Consider allopurinol or switch to TG |
| < 230                     | > 5700                    | Shunting             | Hepatotoxicity                 | Consider allopurinol or 5-ASA or switch to TG |
| 230-400                   | > 5700                    | Possible resistance to thiopurine therapy | Hepatotoxicity                 | Consider allopurinol or 5-ASA |
| > 400                     | > 5700                    | Therapy resistance   | Myelotoxicity                  | Decrease dose |

Therapeutic target of therapy: 6-TGN: 230-400 pmol/8 × 10^8 RBC; 6-MMP: < 5700 pmol/8 × 10^8 RBC. AZA: Increase with 50 mg, MP: Increase with 25 mg; in case of thiopurine refractoriness, consider switch of therapy to non-thiopurine therapy; Allopurinol co-treatment with 100 mg daily requires dose-adjustment of thiopurine therapy to approximately 25%-33% of original daily dose; Treatment with thioguanine in low dose (i.e., 0.3 mg/kg) bypasses the formation of 6-MMP; in case of adverse events. 6-TGN: 6-thioguanine nucleotides; 6-MMP: 6-methylmercaptopurine; RBC: Red blood cells; <: Lower than; <<: Much lower than; >: Higher than; >>: Much higher than; AZA: Azathioprine; MP: Mercaptopurine; TG: Thioguanine; 5-ASA: 5-aminosalicylic acid (mesalazine).

**TG THERAPY**

In those patients with either idiosyncratic (e.g., pancreatitis) adverse events on conventional thiopurine therapy or adverse events based on elevated 6-MMP concentrations, these patients can be switched to TG. In some countries, TG is considered as rescue drug when conventional therapy fails, however, in The Netherlands this drug is officially registered as treatment option for IBD since March 2016. One of the feared complications of TG treatment is the development of nodular regenerative hyperplasia (NRH), a condition of the liver in which patients might develop non-cirrhotic portal hypertension. However, in contrary to earlier observations, the development of NRH is seldomly witnessed in those patients treated with low-dose TG therapy (i.e., 0.3 mg/kg) and furthermore not associated with clinically relevant liver disease. In our patients treated with TG, liver biopsies are only performed in patients with symptoms of portal hypertension or persisting liver test abnormalities and no longer as a routine.

**CANCER RISK**

The use of thiopurines is associated with a three- to fivefold higher risk of the development of lymphoproliferative disorders, in particular non-Hodgkin lymphoma, as well as hepatosplenic T-cell lymphoma, especially in patients without prior Epstein-Barr virus (EBV) exposure. We do not systematically test EBV seroprevalence in patients starting with thiopurines, since over 90% of Dutch inhabitants are exposed to EBV during childhood.

Furthermore, there is a clinically significant elevated risk of developing non-melanoma skin cancer, such as squamous cell carcinoma and basal cell carcinoma. In our centers, we inform our patients of this higher risk and instruct them to, for example, apply sunscreen to unprotected skin and mention newly developed skin lesions directly to the treating physician or IBD-nurse. However, since the absolute incidence of these malignancies in thiopurine-using IBD patients is still low, we do not systematically screen our patients for the existence of these tumors.

**PREGNANCY**

According to recent literature reviews, conventional thiopurine use during pregnancy is not associated with a higher risk of preterm birth, congenital disorders or children with low birth weight. For this reason amongst others, we do not cessate thiopurine therapy in patients that become pregnant, but we refer patients during pregnancy to a dedicated team of gynecologists with interest in IBD. Furthermore, after a successful pregnancy, there is insufficient evidence to discourage patients to give breastfeeding; however, this should always be adjusted to the individual patient wishes. Evidence concerning the use of TG during pregnancy is scarce and further prospective trials are needed to confirm the safety of this thiopurine derivative in pregnant women.

**WHEN TO STOP THIOPURINE THERAPY?**

Whether patients achieving a deep remission may successfully stop thiopurines is not known. In our centers, we continue thiopurine therapy with low threshold, especially in patients with a predicted complex issue.
course (i.e., severe or difficult to manage disease). An exception is the patient with deep prolonged (i.e., $\geq 2-3$ years) remission on thiopurine therapy with no signs of active disease on clinical, biochemical, endoscopic, histological and radiologic evaluation. In these patients, thiopurine therapy could be ceased with a good probability of relapse-free disease.

CONCLUSION
Whereas treatment with thiopurine therapy in IBD patients is hampered by a high number of discontinuations, mostly due to adverse events, several treatment strategies may be applied to maximize effectiveness and optimize safety. With this article, we provided a practical overview on how thiopurine therapy is being prescribed in two of the thiopurine research expert centers in Europe. We provided information concerning pharmacotherapy, indications of thiopurine treatment, toxicity of thiopurines and how to optimize treatment in individual patients using different treatment strategies.

REFERENCES
1. Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, D’Haens G, D’Hoore A, Mantzaris G, Novacek G, Oresland T, Reisch W, Sans M, Stange E, Vermeire S, Travis S, Van Asseldonk DP, Meijer B, Al Hadithy AF, de Boer NK, Peters GJ, Velddkamp AI, Mulder CJ, de Graaf P, Mulder CJ. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012; 6: 991-1030 [PMID: 23040451 DOI: 10.1016/j.crohns.2012.09.002]
2. Dignass A, Van Assche G, Lindsay JO, Léamm L, Söderholm J, Colombel JF, Danese S, D’Hoore A, Gassull M, Gomollón F, Hommes DW, Michetti P, O’Morain C, Oresland T, Windsor A, Stange EF, Travis SP. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management. J Crohns Colitis 2010; 4: 28-62 [PMID: 21122489 DOI: 10.1016/j.crohns.2009.12.002]
3. Chaude N, Patton PH, Tsoulis DJ, Thomas BS, MacDonald JK. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2015; 10: CD000607 [PMID: 26517527 DOI: 10.1002/14651858.CD000607.pub3]
4. Chaude N, Tsoulis DJ, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2013; 4: CD000545 [PMID: 23633304 DOI: 10.1002/14651858.CD000545.pub4]
5. Van Asseldonk DP, de Boer NK, Peters GJ, Veldkamp AI, Mulder CJ, Van Bodegraven AA. On therapeutic drug monitoring of thiopurines in inflammatory bowel disease: pharmacology, pharmacogenomics, drug intolerance and clinical relevance. Curr Drug Metab 2009; 10: 981-997 [PMID: 20214590]
6. Al Hadithy AF, de Boer NK, Derijks LJ, Escher JC, Mulder CJ, Brouwer JS, Thiopurine in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Dig Liver Dis 2005; 37: 282-297 [PMID: 15788214 DOI: 10.1016/j.dld.2004.09.029]
7. de Boer NK, van Bodegraven AA, Harjap B, de Graaf P, Mulder CJ. Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 866-694 [PMID: 18043678 DOI: 10.1038/ncpgasthep1000]
8. Ruemmele FM, Turner D. Differences in the management of pediatric and adult onset ulcerative colitis—lessons from the joint ECCO and ESPGHAN consensus guidelines for the management of pediatric ulcerative colitis. J Crohns Colitis 2014; 8: 1-4 [PMID: 24230969 DOI: 10.1016/j.crohns.2013.10.006]
9. Ruemmele FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC, Amil Dias J, Barabino A, Braegger CP, Bronsky J, Budenos S, Martin-de-Carpi J, De Ridder L, Fagerberg UL, Hugot JP, Kerkvloet J, Kolacek S, Kolektzo S, Lionetti P, Miele E, Navas López VM, Paerregaard A, Russell RK, Serban DE, Shaoul R, Van Rheenen P, Veereman G, Weiss B, Wilson D, Dagnass A, Eliaim A, Winter H, Turner D. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis 2014; 8: 1179-1207 [PMID: 24909831 DOI: 10.1016/j.crohns.2014.04.005]
10. Rosen MJ, Dhawan A, Saced SA. Inflammatory Bowel Disease in Children and Adolescents. JAMA Pediatr 2015; 169: 1053-1060 [PMID: 26414706 DOI: 10.1001/jamapediatrics.2015.1982]
11. Elton GB. The purine path to chemotherapy. Science 1989; 244: 41-47 [PMID: 2649979]
12. Bean RH. The treatment of chronic ulcerative colitis with 6-mercaptopurine. Med J Aust 1962; 49: 592-593 [PMID: 13969929]
13. Karran P, Attard N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer 2008; 8: 24-36 [PMID: 18097462 DOI: 10.1038/ncn2292]
14. Dervieux T, Chu Y, Su P, Chi EW, Ranslev MV, HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphohlasts following mercaptopurine therapy. Clin Chem 2002; 48: 61-68 [PMID: 11751539]
15. Temi A, Schaeffeler E, Herrlingker KR, Klotz U, Schwab M. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet 2007; 46: 187-208 [PMID: 17328579 DOI: 10.2165/00003888-200704030-00001]
16. Zaza G, Cheok M, Krystetskaia N, Thorn C, Stocco G, Hebert JM, McLeod H, Weinshilboum RM, Relling MV, Evans WE; Klein TE, Altman RB. Thiopurine pathway. Pharmacogenet Genomics 2010; 20: 573-574 [PMID: 19952870 DOI: 10.1097/FPG.0b013e3283343388]
17. van Bodegraven AA, van Everdingen DJ, Dijkstra G, de Jong DJ, Oldenburg B, Hommes DW. [Guideline ‘Diagnosis and treatment of inflammatory bowel disease in adults’. I. Diagnosis and treatment]. Ned Tijdschr Geneeskd 2010; 154: A1899 [PMID: 21029496]
18. Frei P, Biedermann L, Nielsen OH, Bogler G. Use of thiopurines in inflammatory bowel disease. World J Gastroenterol 2013; 19: 1040-1048 [PMID: 23467510 DOI: 10.3748/wjg.v19.i7.1040]
19. Goel RM, Blaker P, Mentzer A, Fong SC, Mariani AM, Sanderson JD. Optimizing the use of thiopurines in inflammatory bowel disease. Ther Adv Chronic Dis 2015; 6: 138-146 [PMID: 25954498 DOI: 10.1177/2040622315579063]
20. Colombel JF, Reisch W, Mantzaris GJ, Kornbluth A, Rutgeerts P, Tang KL, Oortwijn A, Bevelander GS, Cornhill FJ, Sandborn WJ. Randomised clinical trial: deep remission in biological and immunomodulator naïve patients with Crohn’s disease - a SONIC post hoc analysis. Aliment Pharmacol Ther 2015; 41: 734-746 [PMID: 25728587 DOI: 10.1111/apt.13139]
21. Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, Panaccione R, Steinhart AH, Tse F, Feagan B. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology 2015; 148: 1035-1058. e3 [PMID: 25747566 DOI: 10.1053/j.gastro.2015.03.001]
22. Côté-Daigneault J, Bouin M, Lahaye R, Colombel JF, Poitrass J. Biologics in inflammatory bowel disease: what are the data? United European Gastroenterol J 2015; 3: 419-428 [PMID: 26535119 DOI: 10.1177/2050646615590302]
23. Colombel JF, Sahnenn W, Reisch W, Mantzaris GJ, Kornbluth A, Rachmilowitz D, Lichtiger S, D’Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2016; 374: 1900-1908 [PMID: 26959239 DOI: 10.1056/NEJMoa1602180]
November 6, 2016 | Volume 7 | Issue 4
Meijer B et al. Treating IBD-patients with thiopurines

pregnancy in inflammatory bowel disease. J Crohns Colitis 2015; 9: 107-124 [PMID: 25602023 DOI: 10.1093/ecco-jcc/jju006]

53 Damas OM, Deshpande AR, Avalos DJ, Abreu MT. Treating Inflammatory Bowel Disease in Pregnancy: The Issues We Face Today. J Crohns Colitis 2015; 9: 928-936 [PMID: 26129693 DOI: 10.1093/ecco-jcc/jjv118]

54 Jharap B, de Boer NK, Stokkers P, Hommes DW, Oldenburg B, Dijkstra G, van der Woode CJ, de Jong DJ, Mulder CJ, van Elburg RM, van Bodegraven AA. Intraterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. Gut 2014; 63: 451-457 [PMID: 23424097 DOI: 10.1136/gutjnl-2012-303615]

55 de Meij TG, Jharap B, Kneepkens CM, van Bodegraven AA, de Boer NK. Long-term follow-up of children exposed intraterine to maternal thiopurine therapy during pregnancy in females with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 38: 38-43 [PMID: 23675854 DOI: 10.1111/apt.12334]

56 Gardiner SJ, Gearry RB, Roberts RL, Zhang M, Barclay ML, Begg EJ. Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs. Br J Clin Pharmacol 2006; 62: 453-456 [PMID: 16995866 DOI: 10.1111/j.1365-2125.2006.02639.x]

57 Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vis M, Guslandi M, Oldenburg B, Dotan I, Marteau P, Ardizzone A, Baumgart DC, D’Haens G, Gionchetti P, Portela F, Vucelic B, Söderholm J, Schaer J, Koletzko S, Kolho KL, Lukas M, Mortet C, Tilg H, Vermeire S, Carbonnel F, Cole A, Novacek G, Reinschagen M, Tienans E, Herrlinger K, Oldenburg B, Bounhui Y, Kiesslich R, Stange E, Travis S, Lindsay J. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Special situations. J Crohns Colitis 2010; 4: 63-101 [PMID: 21122490 DOI: 10.1016/j.crohns.2009.09.009]

58 de Boer NK, Van Elburg RM, Wilhelm AJ, Remmink AJ, Van Vught JM, Mulder CJ, Van Bodegraven AA. 6-Thioguanine for Crohn’s disease during pregnancy: thiopurine metabolite measurements in both mother and child. Scand J Gastroenterol 2005; 40: 1374-1377 [PMID: 16334449]

59 Clarke K, Regueiro M. Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm Bowel Dis 2012; 18: 174-179 [PMID: 21674731 DOI: 10.1002/ibd.21792]

60 Chocair P, Duley J, Simmonds HA, Cameron JS, Ianez L, Arap S, Sabbaga E. Low-dose allopurinol plus azathioprine/cyclosporin/ prednisolone, a novel immunosuppressive regimen. Lancer 1993; 342: 83-84 [PMID: 8100914]

P- Reviewer: Actis GC, Capasso R, Serban DE S- Editor: Ji FF L- Editor: A E- Editor: Lu YJ
